Sanofi Pharma Day 2021

October 18, 2021 8:00 AM - 6:00 PM

MassBioHub & Virtual, 700 Technology Sq Fl 5 Cambridge MA 02139

Add to Calendar 10/18/2021 8:00:00 AM 10/18/2021 6:00:00 PM Sanofi Pharma Day 2021

Accelerate your emerging company or idea at Sanofi’s 2021 Pharma Days on October 18 & 19.  
 

MassBio’s Pharma Days are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. 

Please note that in-person attendees are required to be fully vaccinated to participate in the event. Additionally, masks will be required in all common areas of the event space except for when eating or drinking; in meeting rooms, attendees can remove masks if they feel comfortable doing so.
 

Engage on October 18 from 8 - 9AM ET | Hear from Sanofi leadership during a fireside chat about how Sanofi is evolving to meet the needs of an ever-changing innovation landscape. This livestreamed session will feature: 

  • John Reed, Executive Vice President, Global Head of Research and Development, Sanofi
  • Alban de La Sablière, Head of Partnering, Sanofi
  • Frank Nestle, Global Head of Research, Sanofi


Discover on October 18 from 3 - 4PM ET | Join Sanofi’s information session for the latest insights on its R&D strategy and therapeutic focus areas in immunology and inflammation (I&I) and cell and gene therapies. This hybrid session will feature:

  • John Bertin, Global Head of the Immunology and Inflammation Research Therapeutic Area, Sanofi
  • Christian Mueller, Global Head of Genomic Medicine Unit, Sanofi


Connect on October 18 & 19 | Meet one-on-one with Sanofi representatives to discuss collaboration opportunities. Sanofi’s specific areas of interest are: 

  • Cell and gene therapies, including gene editing and non-viral delivery technologies 
  • Immunology and inflammation, with a focus on dermatology, respiratory, and gastro-intestinal indications   


Eligibility Guidelines
Sanofi is open to connecting with groundbreaking innovators across all stages of development that have a strong understanding of their technology’s path to product. Sanofi is particularly interested in tangible assets or disruptive technologies.

Protection of intellectual property rights (ex. patents, trademarks, copyright, trade secrets, etc.) of your concept is your responsibility and your responsibility alone. Information you include in your application will be shared with Sanofi representatives. Please note that these representatives did NOT sign Non-Disclosure Agreements (NDAs). Therefore, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed. 

MassBioHub & Virtual, 700 Technology Sq Fl 5 Cambridge MA 02139
Global Head of the Immunology and Inflammation Research Therapeutic Area, Sanofi
John Bertin is the Global Head of the Immunology and Inflammation Research Therapeutic Area at Sanofi. He joined Sanofi in 2020 from GlaxoSmithKline where he was Vice-President and Head of Discovery and Early Development for Innate Immunology. John joined GSK in 2008 from Synta Pharmaceuticals where he was Senior Director of Translational Biology. Previously, he was a Senior Scientist in Immuno-Inflammation at Millennium Pharmaceuticals. John is best known for his pioneering work in the fields of cell death and inflammation, including the advancement of the first RIPK1 inhibitor into clinical studies, and contributions towards the discovery of the nodosome and inflammasome signaling complexes. He has co-authored more than 125 scientific articles and has been issued 25 patents on immune targets. John completed his postdoctoral studies at the National Institute of Allergy and Infectious Diseases, National Institutes of Health and at the Institute for Molecular Virology at the University of Wisconsin-Madison. He received his Ph.D. in Microbiology and Immunology from McGill University in Montreal, Canada.

Brought to you by